The barbituric acid derivative bucolome (BCP) is a nonsteroidal anti-inflammatory drug. The present study investigated (hUGT1A1, 1A3, 1A4 , 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17). As a result, BCP-NG formation (pmol equivalents/min/mg protein) was observed with microsomes expressing hUGT1A1 (142), 1A3 (196), 1A4 (8), 1A7 (8), 1A8 (66), 1A9 (38), 1A10 (9), 2B4 (7) and 2B7 (16). In particular, the activity of hUGT1A1 and 1A3 was high. These results suggest that the UGT isoforms responsible for formation of BCP-NG exist in various mammalian species, including humans, and that the UGT 1A family is primarily responsible for BCP N-glucuronide formation in humans.
Introduction
Glucuronic acid conjugation is an enzymatic reaction catalyzed by UDP-glucuronosyltransferase (UGT; EC 2.4.1.17), and it is one of the most important reactions in phase II drug metabolism. UGT is widely present in many species from bacteria to humans, and glucuronic acid conjugation is estimated to account for about 35% of phase II drug metabolism [1] . Bucolome (BCP, Figure 1 ) is a barbituric acid derivative nonsteroidal anti-inflammatory drug that exhibits analgesic and anti-inflammatory actions without having sedative or hypnotic effects, unlike many barbiturates. It has been used for the treatment of rheumatoid arthritis [2] . It has been reported that BCP promotes the secretion of bile in dogs and rats [3, 4] and induces uric acid excretion in humans [5] , so BCP is also used as an antipodagric. In recent years, it has been shown that BCP inhibits CYP2C9 [6] . In patients on warfarin therapy in Japanese hospitals, BCP is often administered concomitantly to maintain the plasma warfarin concentration through inhibition of the metabolism of S-warfarin by CYP2C9 [7] . Although BCP is used for various purposes, as noted above, its metabolic pathway and the enzymes involved in humans have not been evaluated in detail, with only old references being available [5, [8] [9] [10] [11] .
In order to clarify whether the formation of BCP-NG occurs in mammals other than rats, we investigated BCP-NG formation in vitro using liver microsomes from rats, guinea pigs, mice, hamsters, Mongolian gerbils, rabbits, and humans. Although the N-glucosides of amobarbital [12] and phenobarbital [13] have been reported to be the primary metabolites of these barbiturate derivatives in humans, their N-glucuronides have not been identified. Based on the results of BCP-NG formation by human liver microsomes in the present study, we also assessed BCP metabolites in the urine of a patient with hyperuricemia who was administered BCP at 600 mg/day. We found BCP-NG excretion in the urine at 2.5% of the dose over 12 hours. In order to identify the UGT isoforms involved in N-glucuronidation of BCP, we also studied BCP-NG formation using insect cell microsomes expressing 12 different human UGT isoforms (hUGT1A1,  1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15,  and 2B17) .
This report describes the UGT isoforms catalyzing BCP-NG formation in humans.
Materials and Methods

Chemicals, Experimental Animals, and Enzymes
All animal procedures were approved by the Meiji Pharmaceutical University Committee for Ethics of Experimentation and Animal Care (approved No. 2304). BCP was synthesized from cyclohexylurea (Tokyo Chemical Industry Co., Ltd., Tokyo) and n-butylmalonate (Tokyo Chemical Industry) by the method of Senda et al. [2] . Paramidine  (300 mg) was purchased from Aska Pharmaceutical Co., Ltd., (Tokyo). BCP-NG was obtained by the previously reported method [14] . Solutions of BCP and PBZ adjusted to 1 mg/ml with DMSO were used as standard solutions, which were diluted with the solvent immediately before use. Reagents were stored at 30˚C and were used within 3 months.
Male Wistar-ST rats weighing 300 -500 g (clean), male Hartley guinea pigs weighing 550 -700 g (clean), male ddY mice weighing 60 -80 g (SPF), male Syrian hamsters weighing 185 -200 g (SPF), male Mongolian gerbils weighing 60 -63 g (SPF), and male Japanese white rabbits weighing 2.0 -2.2 kg (clean) were all purchased from Japan SLC Inc. (Shizuoka). The animals were housed under conventional conditions until use. Recombinant hUGT isoform microsomes for various human UGT isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17) were expressed in insect cells using a baculovirus and 50-donor pooled human liver microsomes were obtained from BD Gentest (San Jose, CA). All chemicals used were analytical or special grade products, and the water was double-distilled. Liver microsomes of rats, mice, guinea pigs, hamsters, Mongolian gerbils, and rabbits were prepared from 100 g of liver tissue harvested from four animals by the previously reported method [15] . Protein concentrations were determined by the method of Lowry et al. [16] . 
HPLC and Chromatography Conditions
BCP-NG Formation by Liver Microsomes of Humans and Experimental Animals
The concentration of each reagent in the reaction mixture yielding maximum BCP-NG formation was determined in advance using rat liver microsomes (final concentration range tested: lubrol 0 -0.4 mg/ml, rat liver microsomes 0 -5 mg/ml, MgCl 2 0 -10 mM, saccharolactone 0 -8 mM, BCP 0 -5 mM, 0.5 M Tris-HCl pH6 -pH8, UDP-Ga 0 -10 mM, and incubation time 0 -60 min). Enzymatic reactions were performed in a total volume of 250 l containing UDP-Ga (final concentration, 8 mM), liver microsomes solubilized with lubrol (final concentration, 0.1 mg/ml) of each species (rat, mouse, guinea pig, hamster, Mongolian gerbil, rabbit, and human; 2 mg/ml microsomal protein), MgCl 2 (final concentration, 8 mM), saccharo-1,4-lactone (final concentration, 4 mM), BCP (final concentration, 2 mM), and 0.5 M Tris-HCl (pH 7.4) (final concentration, 0.2 M). After the reaction mixture had been preincubated at 37˚C for 5 minutes, the reaction was started by addition of UDP-Ga or BCP at 37˚C for 20 minutes, and then the reaction was stopped by adding 0.5 g ammonium sulfate. After adding 200 ml of an EtOH solution containing 24 M PBZ, the resulting mixture was mixed vigorously for 30 seconds. It was then centrifuged at 18,000 × g for 10 minutes at 4˚C, and 10 l of 0.1% NaHCO 3 was added to 150 l of the supernatant. Next, 10 l of the supernatant was directly injected into the HPLC apparatus and the concentration of BCP-NG formed by the enzymatic reaction was determined using the BCP calibration curve, as described previously [15] . All measurements were performed in triplicate.
Stabilization of BCP-NG
Since BCP-NG was stable under weakly basic conditions, 10 l of 0.1% NaHCO 3 was added to 150 l of supernatant.
Ethanol Extraction Method
An excess of solid ammonium sulfate (0.5 g) was added to the reaction solution, which was mixed vigorously and then centrifuged at 18,000  g for 10 minutes at 4˚C to separate water and EtOH. This procedure using the salting out method is able to transfer highly water-soluble compounds such as glucuronides into the EtOH layer at high concentrations.
K m , V max , and Intrinsic Metabolic Clearance (CL met ) of BCP and UDP-Ga in Experimental Animals
In order to compare BCP-NG formation among the experimental animals tested (rat, guinea pig, mouse, hamster, Mongolian gerbil, and rabbit), the K m , V max , and intrinsic metabolic clearance (CL met = V max /Km) were obtained. To obtain K m and V max values for BCP, its concentration was varied over the range from 0.01 mM to 3 mM. The amount of UDP-Ga used in this reaction was 22 mM for rats, 8 mM for mice, 8 mM for guinea pigs, 6 mM for hamsters, 10 mM for Mongolian gerbils, and 6 mM for rabbits. To obtain K m and V max values for UDP-Ga, its concentration was varied over the range from 0.01 mM to 24 mM. BCP was used at 2 mM in this enzymatic reaction. Human microsomes were pooled from 50 persons. Since both racial differences and interindividual variations are very large, we did not obtain K m and V max values for BCP N-glucuronidation using human liver microsomes, because Homo sapiens is not a homogeneous species. The initial velocity of BCP-NG formation in relation to the BCP dose and UDP-Ga dose was analyzed using Lineweaver-Burk plots. All measurements were performed in triplicate.
Analysis of Urinary BCP and BCP-NG in a Patient with Hyperuricemia
We received written informed consent from a patient to measure the levels of BCP and BCP-NG in the urine. Total urine was collected from a 23-year-old patient with hyperuricemia at 0, 1, 2, 3, 4, 7, 8, 9, and 12 hours after administration of 600 mg of BCP (2 tablets of Paramidin™ 300 mg), and the urine volume and the urinary levels of BCP and BCP-NG concentrations were determined at each sampling point. The pH of the urine samples was adjusted to about 8 by adding solid NaHCO 3 .
To 250 l of urine, 200 l of an EtOH solution contain-ing 24 mM PBZ (IS) and 0.5 g ammonium sulfate were added, followed by vigorous mixing for 30 seconds. After centrifugation at 18,000  g for 10 minutes at 4˚C, 10 l of the supernatant was directly injected into the HPLC apparatus. Urinary BCP and BCP-NG concentrations were determined from the calibration curve for BCP, as previously reported [15] . All measurements were performed in triplicate.
BCP-NG Formation by Human Recombinant UGT Isoform Microsomes
Twelve different human recombinant UGT isoform microsomes (1 mg/ml microsomal protein) were solubilized by adding alamethicin (0.025 mg/ml DMSO solution). Reactions were performed under the same conditions as in the experiment using human liver microsomes and were stopped by adding 500 l of chloroform. After the reaction mixture had been mixed vigorously for 30 seconds, it was centrifuged at 18,000  g for 10 minutes at 4˚C. To 150 l of the supernatant, the same volume of 5 M acetonitrile solution containing PBZ was added, followed by vigorous mixing for 30 seconds and centrifuged at 18,000  g for 10 minutes at 4˚C. To 50 l of the resulting supernatant, 5 volumes of acetonitrile was added. Then the mixture was mixed vigorously again for 30 seconds and centrifuged at 18,000  g for 10 minutes at 4˚C, after which 10 l of the supernatant was injected into the LC/MS apparatus. Measurements were performed in triplicate. Since BCP-NG formation by recombinant human UGT isoform microsomes was very low, the LC/MS system was used to measure BCP-NG levels.
Data Analysis
K m and V max values for BCP and UDP-Ga in the liver microsomes of experimental animals were determined from the experimental data using Michaelis-Menten hyperbolic kinetics and Lineweaver-Burk plots. Kinetic data are expressed as the mean ± S.D. CL met values were calculated with the K m and V max values obtained from Lineweaver-Burk plots. Multiple post-hoc comparisons among three or more groups were done with Scheffe's test [17] . JMP  Statistical Discovery Software (SAS Institute Japan Co., Tokyo) was used for all analyses and the level of significance was p < 0.05 ( ).
Results
HPLC and LC/MS
HPLC
The retention times of BCP, the I.S., and BCP-NG peaks in the urine of a patient administered BCP were about 7.2, 9.9, and 12.9 minutes, respectively. Calibration curves for BCP and BCP-NG were linear over the range from 0.01 to 100 µM with correlation coefficients > 0.99. The detection limits for BCP and BCP-NG were 0.25 ng and 0.06 ng, respectively. Intra-day and inter-day variation of the calibration curves for BCP and BCP-NG was < 5% in both cases.
LC/MS
The retention times of the BCP-NG (m/z = 441.20) and PBZ (I.S., m/z = 307) peaks were about 9.8 and 13.9 minutes, respectively. Calibration curves for BCP-NG were linear over the range from 1.67 ng/ml to 2.07 g/ml with correlation coefficients > 0.99. The detection limit for BCP-NG was 16.7 pg. Intra-day and inter-day variation of the calibration curve for BCP-NG was <5%.
BCP-NG Formation in the Liver Microsomes of Human and Experimental Animals
BCP-NG formation was detected in the liver microsomes of rats, Mongolian gerbils, rabbits, guinea pigs, humans, hamsters, and mice. The level of BCP-NG formation (pmol equivalents/min/mg protein, mean ± S.D.) was as follows: rat; 479 ± 83, Mongolian gerbil; 378 ± 9, rabbit; 275 ± 26, guinea pig; 257 ± 10, human; 242 ± 18, hamster; 177 ± 22, and mouse; 167 ± 15 ( Figure 2) . Liver microsomal BCP-NG formation was highest in the rat (relative comparison = 1), followed by the Mongolian gerbil (0.83), guinea pig (0.54), rabbit (0.54), human (0.50), hamster (0.37), and mouse (0.35). 
Kinetic Analysis of BCP-NG Formation by Liver Microsomes in Experimental Animals
The K m , V max , and CL met values for BCP and UDP-Ga are shown in Tables 1(a) and 1(b) . The kinetic profile of BCP N-glucuronidation for BCP and UDPGa in the liver microsomes of the 6 mammalian species tested showed a single-enzyme Michaelis-Menten pattern, and no sigmoidal kinetics were noted. The rate of BCP-NG formation in relation to the BCP dose and UDP-Ga dose was analyzed using Lineweaver-Burk plots. Statistically significant species differences were observed for the K m , V max , and CL met values of BCP and UDP-Ga.
Analysis of BCP and BCP-NG in the Urine of a Patient with Hyperuricemia
The HPLC chromatogram of urine obtained 2 hours after administration of BCP is shown in Figure 4 . Cumulative BCP excretion in the urine up to 12 hours after administration was about 3 mg, which was about 0.5% of the dose administered. Cumulative BCP-NG excretion was 14.4 mg, which was about 2.5% of the BCP dose.
BCP-NG Formation by Recombinant Human UGT Isoforms
BCP-NG activity was noted in 9 (hUGT 1A1, 1A3, 1A4, 1A7, 1A8, 1A9, 1A10, 2B4, and 2B7) of the 12 hUGT isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17), and was particularly high for hUGT1A1 and 1A3 (Figure 3) . 
Discussion
Although many N-glucuronides have been reported, most of them are compounds that undergo N-glucuronidation, including primary aromatic amines (UGT1A1, 1A4, 1A9), hydroxylamines (UGT1A1, 1A10), amides (2B7), tertiary aliphatic amines (1A4, 2B10), and aromatic N-heterocycles (1A4, 2B7, 2B10). A number of aromatic N-heterocycles with five-and six-member rings, such as imidazoles, pyrazoles, triazines, tetrazoles, and pyridines are subject to N-glucuronidation. However, N-glucuronidation of the pyrimidine skelton of barbiturates has not been mentioned in recent review articles [18] [19] [20] .
There have been a few reports of N-glucosides and N-glucuronides in which glucose or glucuronic acid is directly attached to a nitrogen (N) atom in the pyrimidine skelton of barbiturates. It has been reported that amobarbital and phenobarbital N-glucosides, in which glucose is directly bound to an N atom of the pyrimidine skeleton, are the primary metabolites of barbiturate derivatives in humans, but N-glucuronides of barbiturate derivatives have not been reported to date in humans [12, 13, 21, 22] . Neighbors et al. [23] reported that an N-glucoside and an N-glucuronide were found in the urine of mice administered phenobarbital. BCP-NG, the first N-glucuronide of a barbiturate derivative, has only been reported in rats, but there had been no investigation of whether or not BCP-NG is produced in other species. Therefore, we established an in vitro method to assay BCP-NG formation using rat liver microsomes, and studied BCP-NG formation in the liver microsomes of Mongolian gerbils, guinea pigs, rabbits, hamsters, mice, and humans. BCP-NG formation was observed in all species, but the activity varied greatly among the different species (Figure 2) . These results suggest that UGT isoforms forming BCP-NG exist in a wide range of mammalian species.
We calculated K m , V max , and CL met values for BCP and UDP-Ga under the conditions showing maximum BCP-NG formation by the liver microsomes of rats, Mongolian gerbils, guinea pigs, rabbits, hamsters, and mice (Tables 1(a) and 1(b) ). A significant relation was observed between BCP-NG formation in these 6 animals and the V max and K m values for UDP-Ga (R = 0.925 and R = 0.827, respectively) (Table 1(b) . However, although a significant relation was observed between BCP-NG formation in the 6 animals and V max values for BCP (R = 0.894), no relation was observed between BCP-NG formation and K m values for BCP (R = 0.144). Glucuronic acid conjugation is a two-substrate reaction (BCP and UDP-Ga). It is thus considered that BCP-NG formation occurs as follows: first, UDP-Ga binds to UGT in the endoplasmic reticulum, and then BCP binds to UGT-UDP-Ga complex, resulting in the formation of BCP-NG. Thus, if UGT binds more readily with UDP-Ga, an animal will produce BCP-NG easily, resulting in a high V max value for UDP-Ga.
Luukkanen et al. [24] reported that the glucuronidation of entacapone by UGT1A9 was inhibited by 1-naphthol in an entacapone-competitive fashion and was noncompetitive with respect to UDP-Ga. Inhibition by UDP, on the other hand, was noncompetitive with respect to enta-capone and competitive with respect to UDPGA. They stated that the reaction involved a compulsory ordered bi bi mechanism based on analysis of inhibition profiles, in which UDP-Ga was the first binding substrate and entacapone was the second binding substrate. The mechanism of BCP-NG formation, in which the first binding substrate is UDP-Ga and the second binding substrate is BCP, agrees well with the results of Luukkanen et al. [24] . The differences of kinetic parameters for BCP and UDP-Ga among animal species are believed to be due to complex reactions caused by species differences of UGT isoforms, so when drug metabolism data obtained from laboratory animals are extrapolated to human, differences in the metabolism of animal species must be taken into consideration.
Since BCP-NG was formed by human liver microsomes, we investigated metabolites of BCP in the urine of a patient with hyperuricemia who was administered 600 mg of BCP (2 tablets of Paramidin  300 mg). Our results demonstrated that BCP was metabolized to BCP-NG and excreted in the urine (about 2.5% of the BCP dose over 12 hours) (Figure 4) . Thus, it was clarified that N-glucuronidation is also the primary metabolic pathway of BCP in humans. It is known that N-glucoside is the primary human metabolite of barbiturates, so we investigated BCP N-glucoside formation in human liver microsomes by using UDP-glucose (8 mM) instead of UDP-Ga. After 2 hours of incubation under the same conditions as for BCP-NG formation in vitro, HPLC was performed, but an unknown new peak could not be detected on the chromatogram (data not shown). Further investigation will be needed to determine the factors that select N-glucoside and/or N-glucuronide as the metabolite of barbituric acid derivatives. In order to identify UGT isoforms that catalyze the N-glucuronidation of BCP in humans, we studied BCP-NG formation using microsomes of recombinant insect cells expressing each human UGT isoform (hUGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17) (Figure 3) . As a result, BCP-NG formation was noted in hUGT1A1, 1A3, 1A4, 1A7, 1A8, 1A9, 1A10, 2B4, and 2B7, with the specific activity (pmol equivalents/min/mg protein) being particularly high for 1A1 (142.0) and 1A3 (196.2), followed by 1A8 (66.2), 1A9 (38.3), and 2B7 (15.9). The activity of hUGT1A4, 1A7, 1A10, and 2B4 was 10 pmol equivalents/min/mg protein or lower.
Ohno et al. [25] established a method for the quantification of mRNAs for hUGT isoforms using real-time RT-PCR, and identified and quantified the levels of hUGT mRNA isoforms in various human organs. According to their report, the mRNAs for hUGT1A1, 1A3, 1A5, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B11, 2B15, and 2B17 were found in human liver tissue. The expression of hUGT1A1 mRNA was about 30% of that for hUGT2B7 mRNA, while that of hUGT2B4 mRNA was about 9 times higher than that of 2B7 mRNA. BCP-NG formation by 2B4 and 2B7 was lower than by the UGT1A family, but when their relative abundance in the liver (approximately 27 times that of 1A1 for 2B4 and approximately 3 times that of 1A1 for 2B7) is taken into consideration, 2B4 and 2B7 also seem likely to contribute to the formation of BCP-NG in humans.
In recent years, it has been reported that hepatic UGT1A4 and 2B10 catalyze the N-glucuronidation of aromatic N-heterocycles in humans [18, 19] . However, BCP-NG formation by hUGT1A4 was <10 pmol equivalents/min/mg protein (Figure 3) . The level of hUGT1A4 mRNA in tissues other than the liver is either very low [18, 19] or below the detection limit [25] . Therefore, it seems that the contribution of UGT1A4 to BCP-NG formation is negligible. hUGT2B10 has only been detected in the liver and small intestine [18, 19] , and the level of hUGT2B10 mRNA in the small intestine is only 0.05% of that in the liver. The ortholog of human 2B10 has not been detected in animals [20] , while the UGT1A1 family has been detected in various species [20, [26] [27] and a number of different tissues [28] [29] [30] .
We found that BCP-NG was formed in the liver microsomes of rats, Mongolian gerbils, rabbits, guinea pigs, hamsters and mice, as well as in humans (Figure 2) . Previously, we reported that BCP-NG formation was observed with the microsomal fractions of the liver, small and large intestines, and kidney in rats [30] . It is supposed that the hUGT isoforms catalyzing BCP-NG formation in rats differ from UGT2B10 that is localized to the liver and small intestine in humans. However, microsomes expressing hUGT2B10 are not commercially available, so we could not examine BCP-NG formation directly. Further investigations will be needed to clarify the role of BCP-NG formation by hUGT2B10.
We previously reported that the liver microsomes of UGT1A family-deficient Gunn rats [29] show dramatically low BCP-NG formation (only 8.5% of that in normal rats), while BCP-NG formation by phenobarbitaland clofibric acid-pretreated microsomes was 1.5-and 1.6-fold higher than by untreated microsomes, respectively [31] .
Conclusions
The results obtained in this study suggest that the UGT1A family plays the primary role in the formation of BCP-NG in mammals, including humans, and that UGT2B isoforms may have a complementary role. This is the first report about detection of the N-glucuronide of a barbiturate derivative in humans.
